Cytomegalovirus and Epstein-Barr Infections: Prevalence and Impact on Patients with Hematological Diseases

Silva, Jean de Melo; Pinheiro-Silva, Renato; Dhyani, Anamika; Pontes, Gemilson Soares

doi:10.1155/2020/1627824

Cited by 38 publications

(24 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EBV and CMV infections have been associated with several hematological diseases, especially regarding the progression of hemoglobinopathies, lymphomas, myelomas, hemophilia, sickle cell and aplastic anemia diseases [22]. In this study, patients carriers of ITP showed the highest prevalence rates for EBV infection and EBV/CMV coinfection.…”

Section: Discussionmentioning

confidence: 60%

Epidemiological and Liver Biomarkers Profile of Epstein-Barr Virus Infection and Its Coinfection with Cytomegalovirus in Patients with Hematological Diseases

et al. 2021

Self Cite

View full text Add to dashboard Cite

Epstein-Barr virus (EBV) and cytomegalovirus (CMV) are viruses globally distributed that have been associated with the development and prognosis of many pathologies, including hematological diseases. This study aimed to characterize the epidemiological profile of EBV infection and the infection-correlated hepatic manifestations in patients with hematological diseases of the northern Brazilian state of Amazonas. A total of 228 patients were serologically tested for the presence of anti-EBV and anti-CMV IgG antibodies through an enzyme-linked immunosorbent assay. The coinfection with CMV, sociodemographic and laboratory records of all patients were also assessed. The overall prevalence observed among the study population for EBV infection and EBV/CMV coinfection was 85.09% (95% CI: 0.80–0.90) and 78.51% (95% CI: 0.73–0.84), respectively. The age group 31–40 years old were more susceptible to EBV/CMV coinfection (95% CI: 1.59–93.41, p = 0.011), while young people aged 1–10 years old were less affected for both EBV infection (CI 95%; 0.66–0.91, p = 0.001) and EBV/CMV coinfection (95% CI: 0.52–0.81, p < 0.0001). High serum levels of the liver biomarker ferritin were associated with EBV infection (95% CI: 1.03–1.54, p = 0.031) and EBV/CMV coinfection (95% CI: 1.02–1.70, p = 0.038). Our findings indicated that the elevated prevalence of EBV infection is not associated with the hematological diseases or transfusion rates, but with the socioeconomic status of the study population. Also, this study suggests that the EBV infection and its coinfection with CMV are related to the increase of serum ferritin levels.

show abstract

Section: Discussionmentioning

confidence: 60%

Epidemiological and Liver Biomarkers Profile of Epstein-Barr Virus Infection and Its Coinfection with Cytomegalovirus in Patients with Hematological Diseases

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although the association of EBV with several types of cancer is well documented, this association has not been documented for CMV and only a few studies reported that CMV might be associated with some cancers in humans. In this regard, Silva et al reported that CMV might be associated with hematologic malignancies including myeloid tumors (37). Moreover, CMV has been considered as a potential causative factor in the development of colon cancer (38).…”

Section: Discussionmentioning

confidence: 99%

Association of Epstein–Barr Virus and Cytomegalovirus Infections with Esophageal Carcinoma

et al. 2021

View full text Add to dashboard Cite

Background: Given the fact that viral infections play an important role, either directly or indirectly, in around 20 percent of human cancers, this study aimed at investigating the potential association of Epstein–Barr virus (EBV) and cytomegalovirus (CMV) infections in esophageal cancer that is the sixth most common cause of cancer-related deaths. Methods: In this case-control study, a total of 200 paraffin-embedded biopsies of cancerous and benign esophageal tissues were gathered from the biopsy bank of Imam Reza Hospital, Tabriz, Iran in 2017. All samples were first deparaffinized, and then subjected to commercial DNA extraction. The quality of extracted DNA was evaluated by amplification of the beta globulin gene. Identification of EBV and CMV DNA was performed using primers designed for the EBER region of EBV and the immediate early (IE) region of the CMV genome, respectively. Results: The mean age of the subjects in the test and control groups was 52.2 (17.1) and 59.9 (18.9), respectively. The distribution of gender (male/female) in patient and control groups was 54/46 and 53/47, respectively. Our results showed that the frequency of EBV (P < 0.001) and CMV (P < 0.001) in cancerous samples was statistically higher than control group. Moreover, in the cancerous group the rate of EBV was significantly higher in the esophageal adenocarcinomas (EAC) sample (12 out of 70) than esophageal squamous cell carcinomas (ESCC) (0 out of 30) (P = 0.016) but, in the ESCC group, 17 out of 30 subjects were positive for CMV which was significantly higher in comparison with EAC patients (1 out of 70) (P < 0.001). Conclusions: Findings indicated that EBV and CMV might be contributed to the pathogenesis of EAC and ESCC types of esophageal carcinoma, respectively, although further studies are warranted.

show abstract

“…Herpesvirus reactivations are frequent after solid organ or allogeneic stem cell transplants. CMV reactivation occurs in 12–67% of patients undergoing autologous stem cell transplant and 2–39% oncohematologic non-transplant subjects [ 78 ]. A clear association with alemtuzumab emerged from prospective studies [ 79 ].…”

Section: Viral and Mycobacterial Reactivations During Aiha Treatmementioning

confidence: 99%

Infectious Complications in Autoimmune Hemolytic Anemia

Giannotta

Fattizzo

Cavallaro

et al. 2021

JCM

View full text Add to dashboard Cite

Autoimmune hemolytic anemia (AIHA) may be frequently challenged by infectious complications, mainly as a result of immunosuppressive treatments administered. Furthermore, infectious agents are known triggers of AIHA onset and relapse. Although being risk factors for mortality, infections are an underestimated issue in AIHA. This review will collect the available evidence on the frequency and type of infectious complications in AIHA, detailing the risk related to each treatment (i.e., steroids, rituximab, splenectomy, classic immunosuppressive agents, and new target drugs). Moreover, we will briefly discuss the infectious complications in AIHA secondary to other diseases that harbor an intrinsic infectious risk (e.g., primary immunodeficiencies, systemic autoimmune diseases, lymphoproliferative disorders, solid organ and hematopoietic stem cell transplants). Finally, viral and bacterial reactivations during immune suppressive therapies will be discussed, along with suggested screening and prophylactic strategies.

show abstract

Cytomegalovirus and Epstein-Barr Infections: Prevalence and Impact on Patients with Hematological Diseases

Cited by 38 publications

References 106 publications

Epidemiological and Liver Biomarkers Profile of Epstein-Barr Virus Infection and Its Coinfection with Cytomegalovirus in Patients with Hematological Diseases

Epidemiological and Liver Biomarkers Profile of Epstein-Barr Virus Infection and Its Coinfection with Cytomegalovirus in Patients with Hematological Diseases

Association of Epstein–Barr Virus and Cytomegalovirus Infections with Esophageal Carcinoma

Infectious Complications in Autoimmune Hemolytic Anemia

Contact Info

Product

Resources

About